<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35501715</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2377</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC neurology</Title>
          <ISOAbbreviation>BMC Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic cerebellar degeneration with anti-Yo antibodies and an associated submandibular gland tumor: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>165</StartPage>
          <MedlinePgn>165</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">165</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02684-4</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">As a debilitating syndrome, paraneoplastic cerebellar degeneration (PCD) remains challenging to treat. Further, anti-Yo antibody (directed against human cerebellar degeneration-related protein 2) detection in patients with PCD is associated with unsatisfactory responses to existing therapies. Here, we present the case of a 60-year-old woman who developed PCD with anti-Yo antibodies and a submandibular gland tumor.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 60-year-old woman presented with a 5-day history of unsteadiness of gait and inadequate coordination of her extremities, along with truncal instability. Although walking without aid was possible, dysmetria of all four limbs, trunk, and gait ataxia was observed. While routine biochemical and hematological examinations were normal, the patient's blood was positive for anti-Yo antibodies. When the neurological symptoms deteriorated despite administration of intravenous methylprednisolone, fluorodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) images with contrast enhancement were performed, which showed a tumor in the left submaxillary gland. She underwent total left submandibular gland resection, including the tumor; histological and immunohistochemical results revealed a salivary duct carcinoma. She was administered intravenous methylprednisolone, followed by 10 plasma exchange sessions, intravenous immunoglobulins, and cyclophosphamide therapy. Following treatment, her symptoms were not alleviated, even after the reduction of anti-Yo titers.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although tumor detection was delayed, early tumor detection, diagnosis, and PCD treatment are essential because any delay can result in the progression of the disorder and irreversible neurological damage. Therefore, we recommend that the possibility of a salivary gland tumor should be considered, and whole-body dual-modality CT, including the head and neck, and FDG-PET should be performed at the earliest for patients with well-characterized paraneoplastic antibodies when conventional imaging fails to identify a tumor.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Imai</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0001-9905-820X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kawasaki Municipal Tama Hospital: Kawasaki Shiritsu Tama Byoin, 1-30-37, Shukugawara Tama-ku Kawasaki-shi, Kawasaki, Kanagawa, Japan. t2imai@marianna-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shinohara</LastName>
            <ForeName>Kensuke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kawasaki Municipal Tama Hospital: Kawasaki Shiritsu Tama Byoin, 1-30-37, Shukugawara Tama-ku Kawasaki-shi, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Uchino</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kawasaki Municipal Tama Hospital: Kawasaki Shiritsu Tama Byoin, 1-30-37, Shukugawara Tama-ku Kawasaki-shi, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Okuma</LastName>
            <ForeName>Hirohisa</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Kawasaki Municipal Tama Hospital: Kawasaki Shiritsu Tama Byoin, 1-30-37, Shukugawara Tama-ku Kawasaki-shi, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maki</LastName>
            <ForeName>Futaba</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Shin Yurigaoka General Hospital: Shinyurigaoka Sogo Byoin, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hiruma</LastName>
            <ForeName>Kiyoshi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Otorhinolaryngology, Kawasaki Municipal Tama Hospital: Kawasaki Shiritsu Tama Byoin, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ariizumi</LastName>
            <ForeName>Yasushi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Diagnostic Pathology, St Marianna University School of Medicine Yokohama Seibu Hospital: Sei Marianna Ika Daigaku Yokohama-shi Seibu Byoin, Yokohama, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamano</LastName>
            <ForeName>Yoshihisa</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Division of Neurology, St Marianna University School of Medicine: Sei Marianna Ika Daigaku, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Neurol</MedlineTA>
        <NlmUniqueID>100968555</NlmUniqueID>
        <ISSNLinking>1471-2377</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000912">Antibodies, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000719013">anti-Yo autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
          <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>X4W7ZR7023</RegistryNumber>
          <NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000912" MajorTopicYN="N">Antibodies, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013365" MajorTopicYN="Y">Submandibular Gland Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anti-Yo antibodies</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndrome</Keyword>
        <Keyword MajorTopicYN="N">Salivary duct carcinoma</Keyword>
        <Keyword MajorTopicYN="N">Submandibular gland tumor</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>0</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35501715</ArticleId>
        <ArticleId IdType="pmc">PMC9059384</ArticleId>
        <ArticleId IdType="doi">10.1186/s12883-022-02684-4</ArticleId>
        <ArticleId IdType="pii">10.1186/s12883-022-02684-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–340. doi: 10.1016/S1474-4422(08)70060-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(08)70060-7</ArticleId>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams'ili S, Grefkens J, De Leeuw B, Bent M, Hooijkaas H, Holt B, et al.  Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(6):1409–1418. doi: 10.1093/brain/awg133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg133</ArticleId>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Wildemann B. 'Medusa-head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII. J Neuroinflammation. 2015;12:166. doi: 10.1186/s12974-015-0356-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0356-y</ArticleId>
            <ArticleId IdType="pmc">PMC4574226</ArticleId>
            <ArticleId IdType="pubmed">26377085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yshii L, Bost C, Liblau R. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. Front Immunol. 2020;11:991. doi: 10.3389/fimmu.2020.00991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00991</ArticleId>
            <ArticleId IdType="pmc">PMC7326021</ArticleId>
            <ArticleId IdType="pubmed">32655545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannoth S. Paraneoplastic neurologic syndrome: A practical approach. Ann Indian Acad Neurol. 2012;15(1):6–12. doi: 10.4103/0972-2327.93267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0972-2327.93267</ArticleId>
            <ArticleId IdType="pmc">PMC3299076</ArticleId>
            <ArticleId IdType="pubmed">22412264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al.  A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi: 10.1016/S1474-4422(15)00401-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00401-9</ArticleId>
            <ArticleId IdType="pmc">PMC5066574</ArticleId>
            <ArticleId IdType="pubmed">26906964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42(10):1931–7. doi: 10.1212/WNL.42.10.1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.42.10.1931</ArticleId>
            <ArticleId IdType="pubmed">1407575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Key RG, Root JC. Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review. Psychooncology. 2013;22(9):2152–2155. doi: 10.1002/pon.3270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pon.3270</ArticleId>
            <ArticleId IdType="pubmed">23585287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilmore CP, Elliott I, Auer D, Maddison P. Diffuse cerebellar MR imaging changes in anti-Yo positive paraneoplastic cerebellar degeneration. J Neurol. 2010;257(3):490–491. doi: 10.1007/s00415-009-5407-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5407-9</ArticleId>
            <ArticleId IdType="pubmed">19943166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giometto B, Marchiori GC, Nicolao P, Scaravilli T, Lion A, Bardin PG, et al.  Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathol Appl Neurobiol. 1997;23(6):468–474. doi: 10.1111/j.1365-2990.1997.tb01323.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2990.1997.tb01323.x</ArticleId>
            <ArticleId IdType="pubmed">9460712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, et al.  Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55(5):713–715. doi: 10.1212/WNL.55.5.713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.5.713</ArticleId>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55–62. doi: 10.1215/S1152851703000395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1215/S1152851703000395</ArticleId>
            <ArticleId IdType="pmc">PMC1871966</ArticleId>
            <ArticleId IdType="pubmed">14769141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Y, Abbas J, Wu X, Dooley J, Amburg AL. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol. 1999;75(1):178–183. doi: 10.1006/gyno.1999.5553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/gyno.1999.5553</ArticleId>
            <ArticleId IdType="pubmed">10502450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995;52(8):814–818. doi: 10.1001/archneur.1995.00540320098016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1995.00540320098016</ArticleId>
            <ArticleId IdType="pubmed">7639633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003;63(2):187–190. doi: 10.1023/A:1023931501503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1023931501503</ArticleId>
            <ArticleId IdType="pubmed">12825823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, et al.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127(10):2331–2338. doi: 10.1093/brain/awh247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awh247</ArticleId>
            <ArticleId IdType="pubmed">15361417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vatankulu B, YilmazAksoy S, Asa S, Sager S, Sayman HB, Halac M, et al.  Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Rev Esp Med Nucl Imagen Mol. 2016;35(1):17–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26260889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE. Treatment of paraneoplastic neurologic disorders. Curr Treat Options Neurol. 2010;12(3):212–230. doi: 10.1007/s11940-010-0066-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11940-010-0066-9</ArticleId>
            <ArticleId IdType="pubmed">20842583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol. 1994;78(1):64–73. doi: 10.1016/0030-4220(94)90119-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0030-4220(94)90119-8</ArticleId>
            <ArticleId IdType="pubmed">8078666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer. 1996;77(2):223–30. doi: 10.1002/(SICI)1097-0142(19960115)77:2&lt;223::AID-CNCR1&gt;3.0.CO;2-N.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0142(19960115)77:2&lt;223::AID-CNCR1&gt;3.0.CO;2-N</ArticleId>
            <ArticleId IdType="pubmed">8625227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar RV, Kini L, Bhargava AK, Mukherjee G, Hazarika D, Shenoy AM, et al.  Salivary duct carcinoma. J Surg Oncol. 1993;54(3):193–198. doi: 10.1002/jso.2930540315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.2930540315</ArticleId>
            <ArticleId IdType="pubmed">8412179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Epivatianos A, Dimitrakopoulos J, Trigonidis G. Intraoral salivary duct carcinoma: a clinicopathological study of four cases and review of the literature. Ann Dent. 1995;54(1–2):36–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8572543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer. 1993;72(5):1503–1512. doi: 10.1002/1097-0142(19930901)72:5&lt;1503::aid-cncr2820720503&gt;3.0.co;2-k.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(19930901)72:5&lt;1503::aid-cncr2820720503&gt;3.0.co;2-k</ArticleId>
            <ArticleId IdType="pubmed">7688652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29(10):907–912. doi: 10.1002/hed.20614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.20614</ArticleId>
            <ArticleId IdType="pubmed">17563907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, Graaf W, et al.  Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol. 2011;29(16):473–476. doi: 10.1200/JCO.2010.32.8351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.32.8351</ArticleId>
            <ArticleId IdType="pubmed">21220610</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
